Key Highlights
- CRSP shares tumbled as much as 11.59% during Friday’s session, bottoming at $51.21
- First quarter results disappointed: EPS of -$1.37 versus consensus -$1.15; revenue of $0.86M versus $4.72M forecast — representing a 97.8% decline from the prior year
- Competitor Regeneron’s latest gene therapy approval, Otarmeni, will be distributed at no cost to qualifying American patients, creating potential pricing headwinds for Casgevy
- Chief Executive Samarth Kulkarni divested 10,349 shares on March 16; company insiders have collectively sold 51,828 shares in the last quarter
- Wall Street consensus remains at “Moderate Buy” with a mean price objective of $64.53
CRISPR Therapeutics ($CRSP) experienced a challenging trading session on Friday. Shares plummeted by as much as 11.59%, touching an intraday low of $51.21, ultimately closing near $51.04 — a significant retreat from Thursday’s closing price of $55.18. Trading volume registered approximately 1.36 million shares, running about 27% lighter than typical daily activity.
The sharp decline stemmed from a confluence of two negative developments: disappointing quarterly financial results and emerging competitive dynamics from Regeneron.
Regarding financial performance, CRISPR disclosed earnings per share of -$1.37 for the period, falling short of Wall Street’s -$1.15 projection. Quarterly revenue registered merely $0.86 million — dramatically below the anticipated $4.72 million. This represents a staggering 97.8% contraction compared to the same period last year, shocking market participants.
The biotechnology firm’s return on equity remains negative at -26.31%, accompanied by substantially negative net margins. Analyst projections currently anticipate full-year EPS of -$4.93.
Competitive Threat from Regeneron’s No-Cost Therapy
The secondary catalyst driving the selloff involves Regeneron’s recent development. The pharmaceutical giant secured regulatory approval for Otarmeni, a gene therapy treatment that will be provided without charge to qualified American patients. This represents a significant challenge to the broader gene-editing industry.
CRISPR’s premier product, Casgevy — co-developed alongside Vertex Pharmaceuticals — commands a sticker price of $2.2 million. Market observers worry that Regeneron’s zero-cost approach could trigger broader pricing discussions throughout the sector, potentially undermining the value proposition of high-priced single-administration treatments.
Casgevy achieved distinction as the inaugural CRISPR-based treatment to receive FDA authorization, marking a historic breakthrough. However, marketplace adoption has progressed slower than anticipated, and Regeneron’s announcement introduces additional questions regarding future revenue trajectories.
Executive Stock Sales Compound Investor Concerns
Recent insider transactions have contributed to negative sentiment. Chief Executive Samarth Kulkarni liquidated 10,349 shares on March 16 at a mean price of $48.26, trimming his holdings by roughly 4%. General Counsel James Kasinger simultaneously disposed of 3,450 shares.
During the preceding three-month period, company insiders have collectively offloaded 51,828 shares, representing approximately $2.58 million in total value. Current insider ownership stands at 4.30% of outstanding equity.
While such selling activity isn’t uncommon among biotech leadership managing stock-based compensation, it nevertheless reinforces the cautious atmosphere surrounding the shares.
From an analyst perspective, the outlook remains varied yet moderately optimistic. Bank of America maintains a Buy recommendation with an $89 price objective. Needham carries a Buy rating paired with an $82 target. TD Cowen holds a Hold designation with a $45 forecast. Citizens JMP rates the stock Market Outperform with an $80 target. The aggregate rating registers as Moderate Buy, featuring an average price target of $64.53 — substantially above present trading levels.
The equity’s 50-day moving average sits at $52.68 while the 200-day moving average stands at $55.70. Market capitalization approximates $4.90 billion with a beta coefficient of 1.80.
Current trading activity places CRSP around $51, continuing to trade beneath both major technical averages.
